Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PPP2R2B antisense RNA 1 (PPP2R2B-AS1) is a long non-coding natural antisense transcript bidirectionally transcribed at the PPP2R2B locus, overlapping with exon 7 of the PPP2R2B protein coding gene. The expanded form of this RNA, containing pathological CUG repeats, is associated with neurotoxicity and may contribute to the pathogenesis of spinocerebellar ataxia type 12 (SCA12). Expanded PPP2R2B-AS1 forms RNA foci that sequester splicing factors, induces apoptosis in neuronal models via altered RNA-protein interactions, and can produce proteins via repeat-associated non-ATG (RAN) translation. The transcript is polyadenylated, and full-length characterization is ongoing. Therapeutic targeting of PPP2R2B-AS1 may represent a potential strategy in SCA12, but its low abundance and incomplete annotation present experimental challenges. No specific biological, therapeutic, or drug interaction data exist for PPP2R2B-AS2, and it is likely a synonym or unvalidated entry.
N/A (No drugs identified; targeting this RNA may involve antisense oligonucleotide approaches, but no clinical drugs exist)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PPP2R2B antisense RNA 1 (PPP2R2B-AS1).